faculty photo

Alexis Ogdie-Beatty, MD, MSCE

Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Graduate Group Affiliations

Contact information
3400 Spruce Street
5 White Building
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
Office: 215-662-2454
Fax: 215-662-4500
University of Minnesota, 2002.
Georgetown University School of Medicine, 2006.
University of Pennsylvania, 2012.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Thrastardottir T, Meer E, Hauksdottir A, Gudbjornsson B, Kristinsson SY, Ogdie A, Love TJ.: Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen. Rheumatology (Oxford) Apr 2022.

Eder L, Tony HP, Odhav S, Agirregoikoa EG, Korkosz M, Schwartzman S, Sprabery AT, Gellett AM, Park SY, Bertram CC, Ogdie A.: Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials. Rheumatol Ther Apr 2022.

Coates LC, de Wit M, Buchanan-Hughes A, Smulders M, Sheahan A, Ogdie AR.: Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. Rheumatol Ther Apr 2022.

Mease PJ, Blachley T, Dube B, McLean RR, Kim N, Hur P, Ogdie A.: Effectiveness of 6-Month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol Apr 2022.

Mease PJ, Gladman DD, Merola JF, Deodhar A, Ogdie A, Collier DH, Liu L, Kavanaugh A.: Potential Impact of Sex and Body Mass Index on Response to Therapy in Psoriatic Arthritis: Post-hoc Analysis of Results From the SEAM-PsA Trial. J Rheumatol Apr 2022.

Mease PJ, Kavanaugh A, Ogdie A, Wells AF, Bergman M, Gladman DD, Richter S, Teng L, Jardon S, Smolen JS.: Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase 3 Results in DMARD-Naive Patients With Psoriatic Arthritis. J Rheumatol Apr 2022.

Nguyen T, Churchill M, Levin R, Valenzuela G, Merola JF, Ogdie A, Orbai AM, Scher JU, Kavanaugh A, Kianifard F, Rollins C, Calheiros R, Chambenoit O.: Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. J Rheumatol Apr 2022.

Ogdie A, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh J.: Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry. Rheumatol Ther Mar 2022.

Mease PJ, Chakravarty SD, McLean RR, Blachley T, Kawashima T, Lin I, Kavanaugh A, Ogdie A.: Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatol Feb 2022.

Katz G, Ogdie A, Baker JF, George MD.: Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis. Clin Rheumatol Jan 2022.

back to top
Last updated: 05/03/2022
The Trustees of the University of Pennsylvania